Now Live: Cboe Europe real-time data for all major European stocks.
opens in 23h 9m
Market closed

Pre-market opens in 17 hours 39 minutes
Main market opens in 23 hours 9 minutes

10:20
00:00
23:59

Trading Hours (Monday - Friday):

Pre-market
04:00 - 09:30
Main market
09:30 - 16:00
Post-market
16:00 - 20:00
All times are displayed in the America/New_York timezone (EDT, UTC-04:00).
13.79000 USD
0.09
0.66%
Last update Apr 2, 3:59 PM EDT
Market closed
Day range
13.44000
13.80500
Previous close
13.70000
Open
13.44000
Access this stock data via API
Subscribe
InMode Ltd.
13.79
0.09
0.66%

Overview

Access /time_series data via our API — starting from the Basic plan and above.

Description

InMode Ltd. designs, develops, manufactures, and markets innovative medical aesthetic devices powered by proprietary radiofrequency technology. The company specializes in minimally invasive platforms for procedures like liposuction with skin tightening, body and face contouring, ablative skin rejuvenation, and treatments for women's health conditions. Its non-invasive products address permanent hair reduction, facial rejuvenation, wrinkle reduction, cellulite treatment, skin texture improvement, and superficial vascular or pigmented lesions. Additionally, hands-free devices target skin tightening, fat reduction, and muscle stimulation. InMode Ltd. serves specialties including plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. Products reach physicians and clinics in the United States, Canada, Europe, Japan, Australia, India, and other international markets through a network of distributors. Founded in 2008 and headquartered in Yokneam, Israel, InMode Ltd. plays a key role in advancing radiofrequency-based solutions for aesthetic and wellness procedures worldwide.

About

CEO
Mr. Moshe Mizrahy
Employees
660
Address
Tavor Building
Sha’ar Yokneam PO Box 533
Yokne'am, 2069206
Phone
972 4 909 6313
Website
Instrument type
Common stock
Sector
Healthcare
Industry
Medical Devices
Country
United States
MIC code
XNGS
Access /profile data via our API — starting from the Grow plan (individual) and the Venture plan (business) and above.

Latest press releases

Feb 26, 2026
InMode to Present at Upcoming Investor Conferences

YOKNEAM, Israel, Feb. 26, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences in March:

INMODE Logo

Barclays 28th Annual Global Healthcare Conference

Presenters: Yair Malca, Chief Financial Officer 

Format: In-person fireside chat moderated by Matt Miksic, Senior Equity Analyst, and one-on-one meetings

Location: Miami, FL

When: Wednesday, March 11 at 12:30 pm ET

A live webcast of the presentation can be accessed here.

Oppenheimer 36th Annual Healthcare MedTech & Services Conference

Presenters: Moshe Mizrahy, Chief Executive Officer and Yair Malca, Chief Financial Officer

Format: Virtual fireside chat moderated by Suraj Kalia, Senior Equity Analyst, and one-on-one meetings

When: Monday, March 16 at 1:20 pm ET

A live webcast of the presentation can be accessed here.

About InMode

InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.

Forward-Looking Statements

The information in this press release includes forward-looking statements within the meaning of the federal securities laws. These statements generally relate to future events or InMode's future financial or operating performance, including the 2026 revenue projection described above. Actual outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. In some cases, you can identify these statements because they contain words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," "would" and similar expressions that concern our expectations, strategic plans or intentions. Forward-looking statements are based on management's current expectations and assumptions, and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Consequently, actual results could differ materially from those indicated in these forward-looking statements. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements included in InMode's Annual Report on Form 20-F filed with the Securities and Exchange Commission on February 4, 2025, and our subsequent public filings. InMode undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which pertain only as of the date of this press release.

Investor Relations Contact:

Miri Segal-Scharia

MS-IR LLC

ir@inmodemd.com 

Logo - https://mma.prnewswire.com/media/1064477/InMode_Logo.jpg

Cision View original content:https://www.prnewswire.com/news-releases/inmode-to-present-at-upcoming-investor-conferences-302697407.html

SOURCE InMode LTD

Feb 23, 2026
InMode Announces Conclusion of Independent Transaction Committee Review

YOKNEAM, Israel, Feb. 23, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) a leading global provider of innovative medical technologies ("InMode" or the "Company"), today announced that the independent transaction committee of its Board of Directors (the "Committee") has completed its review of proposals received in connection with a potential transaction.

InMode Logo

 

Since its formation, the Committee has conducted a comprehensive and independent process to evaluate proposals received over the course of its work, with the assistance of external financial and legal advisors.

Following a careful review of the final proposals received in connection with the potential transaction, the Committee has concluded that none of the final proposals is adequate and in the best interests of the Company and its shareholders. Accordingly, the Committee has determined to discontinue the process at this time.

The Company will continue to review and evaluate its business and growth strategy, as well as its cash allocation strategy, with a focus on enhancing long-term shareholder value.

The Company does not intend to provide further updates regarding this matter unless and until it determines that additional disclosure is appropriate or required.

About InMode

InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radio frequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.

Forward-Looking Statements

The information in this press release includes forward-looking statements within the meaning of the federal securities laws. Actual outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. In some cases, you can identify these statements because they contain words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," "would" and similar expressions that concern our expectations, strategic plans or intentions. Forward-looking statements are based on management's current expectations and assumptions, and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Consequently, actual results could differ materially from those indicated in these forward-looking statements. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements included in InMode's Annual Report on Form 20-F filed with the Securities and Exchange Commission on February 10, 2026, and our future public filings. InMode undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which pertain only as of the date of this press release.

Logo - https://mma.prnewswire.com/media/1064477/InMode_Logo.jpg

Contacts

Miri Segal

MS-IR LLC

ir@inmodemd.com

Cision View original content:https://www.prnewswire.com/news-releases/inmode-announces-conclusion-of-independent-transaction-committee-review-302694503.html

SOURCE InMode Ltd.

Access /press_releases data via our API — starting from the Basic plan and above.
Market closed

Pre-market opens in 17 hours 39 minutes
Main market opens in 23 hours 9 minutes

10:20
00:00
23:59

Trading Hours (Monday - Friday):

Pre-market
04:00 - 09:30
Main market
09:30 - 16:00
Post-market
16:00 - 20:00
All times are displayed in the America/New_York timezone (EDT, UTC-04:00).